An observational study in Sepsis, sponsored by Prenosis, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Prenosis, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this prospective cohort device study is to assess clinical usage and impact, diagnostic performance, and prognostic performance of the Sepsis ImmunoScore.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
This study's planned enrollment of 5,000 is above the median of 150 across 1,166 observational studies indexed under Sepsis.
Browse Sepsis studies →Prenosis, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults 18 years or older presenting to the hospital or ED, suspected of clinically significant events, including sepsis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnostic Test: Sepsis ImmunoScore
The Sepsis ImmunoScore is a risk stratification tool that uses Artificial Intelligence/Machine Learning to aid in the identification of patients likely to have or progress to sepsis within 24 hours of assessment.
Sepsis diagnosis
meeting sepsis-3 criteria within 24 hours of Sepsis ImmunoScore order
Time frame: 24 hours
SEP-1 bundle compliance
proportion of patients meeting SEP-1 bundle criteria for whom all bundle components are delivered within the required time frame
Time frame: through study completion, an average of 1 year
Number of clinically significant events such as infection, sepsis, critical care interventions, escalation of care, mortality
(e.g., vasopressor support, renal replacement therapy, non-invasive or invasive respiratory ventilation)
Time frame: through study completion, an average of 1 year
Time to antibiotic administration
Time frame: through study completion, an average of 1 year
Coding compliance including appropriate clinical documentation to justify a diagnosis of sepsis
Time frame: through study completion, an average of 1 year
Hospital length of stay
Time frame: through study completion, an average of 1 year
ICU length of stay
Time frame: through study completion, an average of 1 year
Total charges
Time frame: through study completion, an average of 1 year
In-hospital mortality rate
28-day in-hospital mortality rate defined as the proportion of patients with a discharge disposition of "died" prior to 28 days
Time frame: through study completion, an average of 1 year
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Dec 2027, 20 months later.
Of 52 industry-sponsored observational studies under Sepsis, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 44. This study's planned 20 months is above that.
Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prenosis, Inc.